• 9430 Key West Avenue Rockville, MD 20850 I (240) 268.1141

Cellphire Awarded Grant to Develop Elephant Endotheliotropic Herpesvirus (EEHV) Freeze Platelet Treatment

July 31, 2017

Thanks to a grant from the International Elephant Foundation, Cellphire, Smithsonian Global Health Program, Ringling Bros. Center for Elephant Conservation, Fort Worth Zoo and Houston Zoo have made great strides in developing a novel treatment for a lethal virus afflicting baby Asian elephants around the globe.  Elephant Endotheliotropic Herpesvirus (EEHV) is the leading cause of death among captive Asian elephants under 12 years of age.  EEHV attacks blood vessels and frequently causes uncontrolled hemorrhage, causing the victim to die of blood loss.

The innovative treatment under development builds off of cutting-edge research in human platelet-products, a specialty of Cellphire.  This ground-breaking treatment is shelf-stable and can stop bleeding from trauma and internal damage.  The human product is targeted at situations as diverse as battlegrounds and Ebola outbreaks.  Until now, there has not been a version for elephants.  The biotech firm is aided by the extensive elephant health expertise from partner zoological veterinarians at diverse institutions.  To date, blood from two Asian Elephants has been collected, stabilized, and prepared for separation into component parts.  Separation was successful, and scientists isolated platelet-rich plasma, which was then freeze-dried using a proprietary process.  The resulting lyophilized platelets are being subjected to a battery of quality control tests to evaluate shape, size, identity, activity, and purity.  So far, the platelet product reconstitutes appropriately and contains adequate size and number of particles.  Samples have been tested for sterility, and the product meets or exceeds FDA regulations for an injectable blood product’s sterility.  The product also passes tests for bacterial endotoxin.  Partners are currently focused on optimizing protocols to appropriately utilize antibodies for confirmation of identity and purity.  Assessing in vitro potency for activation and clot formation.  These complicated laboratory procedures are designed to ensure that the final result is a treatment that is safe, effective, and reliable as a treatment for stopping the dangerous hemorrhage caused by EEHV

# # #

 About Cellphire, Inc. 

Cellphire, Inc. (www.cellphire.com) is working to solve the ubiquitous shortage of platelets for treatment of traumatic bleeding and other blood-related problems.  Platelets are critical to the body’s vascular system, responsible for the body’s ability to stop bleeding.  Unlike other blood products that can be frozen and stockpiled for use when needed, platelets must be stored at room temperature, and they spoil after just five days. Cellphire’s lead product, Thrombosomes®, a human platelet-derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a powder that can be stored for years, then reconstituted and brought back to life with sterilized water. Cellphire’s platform technology has tremendous potential across a wide range of medical applications from trauma to wound care, anti-coagulant reversal, imaging, targeted drug delivery and regenerative medicine.  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Thomas Dann
(240) 268-2489
tdann@cellphire.com

 

Source:  Cellphire, Inc.